Acute Coronary Syndrome Management with Antithrombotics

A Stanford Cardiovascular Institute expert details a recent review into managing a growing field of agents.

Video highlights

0:05 Introduction
1:14 Dual antiplatelet therapies
3:13 Ticagrelor’s role
4:11 Complementary anticoagulants
5:33 Evidential trials
6:00 Individualized cardiology care
7:45 Patient populations in need

In an era of quickly evolving guidelines and available agents to respond to post-acute coronary syndrome (ACS), clinicians could benefit from an overarching review of topline therapies and the means to tailored care through antithrombotics.

Fatima Rodriguez, MD, MPH, and Robert A. Harrington, MD, of the Stanford Cardiovascular Institute, recently penned such a review for The New England Journal of Medicine.

In their review of the rapidly progressing classes of antithrombotic therapies—and the large-scale trials which dictate the utility of such drugs—Rodriguez and Harrington aimed to provide a more comprehensive guidance to navigating antiplatelets, anticoagulants, relevant research interpretations, and individualized treatment decisions.

Additionally, they provided perspective on what recommendations cannot be currently evidenced—namely, where gaps in research still persist, and what benefit would be served from filling them.

In an interview with HCPLive above, Rodriguez provides a review of her and Harrington’s work, and shared her thoughts on future antithrombotic guidance in post-ACS.